Glycogen storage disease type III other diagnostic studies: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
=== | ===Molecular genetic testing=== | ||
* | *[[Molecular]] [[genetic testing]] shows biallelic [[pathogenic]] variants in AGL gene for patients with GSD type 3. | ||
*Methods for [[molecular]] [[genetic testing]] include: | |||
**Single-gene testing | |||
**Multi-gene panel | |||
*[[ | |||
==References== | ==References== |
Revision as of 18:22, 18 December 2017
Glycogen storage disease type III Microchapters |
Differentiating Glycogen storage disease type III from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glycogen storage disease type III other diagnostic studies On the Web |
American Roentgen Ray Society Images of Glycogen storage disease type III other diagnostic studies |
FDA on Glycogen storage disease type III other diagnostic studies |
CDC on Glycogen storage disease type III other diagnostic studies |
Glycogen storage disease type III other diagnostic studies in the news |
Blogs on Glycogen storage disease type III other diagnostic studies |
Risk calculators and risk factors for Glycogen storage disease type III other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Other Imaging Findings
Molecular genetic testing
- Molecular genetic testing shows biallelic pathogenic variants in AGL gene for patients with GSD type 3.
- Methods for molecular genetic testing include:
- Single-gene testing
- Multi-gene panel